Core Laboratories INC /DE/ Form 4 insider transactions

Lawrence Bruno, Chairman and CEO and a Director of Core Laboratories Inc. /DE/, purchased 5,000 shares of common stock on July 31, 2026 for $10.78 per share.

Sow Hang Teo, CAO & Treasurer of Core Laboratories Inc. /DE/, reported multiple transactions in common stock on August 1, 2026.

Mark Damian Tattoli, SVP, Gen Counsel & Secretary of Core Laboratories Inc. /DE/, reported multiple transactions in common stock on August 1, 2026.

Mark Tattoli, SVP, Gen Counsel & Secretary of Core Laboratories Inc., reported transactions involving company stock on May 1, 2026.

Katherine Murray, a Director at Core Laboratories Inc., has acquired 8,069 shares of common stock.

Director Curt Anastasio of Core Laboratories Inc. reported transactions involving restricted shares, with a portion vesting and a new grant of restricted shares.

Core Laboratories Director Harvey Robert Klingensmith reported the acquisition of 8,069 shares of common stock.

Core Laboratories Director Temeng Kwaku acquired 8,069 shares of common stock.

Robert F. Martinovich, a Director at Core Laboratories Inc., reported transactions involving restricted shares and common stock on April 1, 2026.

Director Martha Z. Carnes of Core Laboratories Inc. reported the acquisition of 8,069 shares of common stock on April 1, 2026, as part of a transaction plan.

Core Laboratories Inc. awarded 33,490 performance shares to SVP Mark Damian Tattoli, vesting based on ROIC targets over a three-year period.

Core Laboratories Inc. SVP Gwendolyn Gresham received an award of 33,490 performance shares tied to ROIC and TSR metrics over a three-year period.

Core Laboratories Inc.'s SVP & CFO, Christopher Scott Hill, reported the grant of 70,008 performance shares and a correction regarding 59 401(k) plan shares.

Core Laboratories Inc. Chairman and CEO Lawrence Bruno received an award of 204,340 performance shares tied to ROIC and TSR metrics over a three-year period.

Core Laboratories' CAO & Treasurer, Teo Sow Hang, was granted 7,526 performance shares tied to Return on Invested Capital targets.

Core Laboratories Inc. SVP Mark Tattoli vested 24,952 performance shares after the company exceeded its return on invested capital target.

Core Laboratories Inc. SVP Gwendolyn Gresham vested 24,952 performance shares and disposed of 19,301 shares for tax purposes following strong company performance.

Core Laboratories' SVP & CFO, Christopher Scott Hill, vested 61,417 performance shares and disposed of 32,152 shares for tax purposes.

Core Laboratories Inc. CEO Lawrence Bruno vested 180,722 performance shares after the company exceeded return on invested capital targets, increasing his direct ownership.

Core Laboratories Inc. CAO & Treasurer Teo Sow Hang reported the acquisition of 864 common shares from restricted stock vesting and the disposition of 340 shares for tax withholding.

Core Laboratories' SVP, General Counsel & Secretary, Mark Damian Tattoli, reported the vesting of 700 restricted shares and the disposition of 276 shares for tax purposes.

Core Laboratories' CAO & Treasurer, Teo Sow Hang, reported the exercise of restricted shares and the disposition of shares for tax purposes.

Core Laboratories Inc. SVP Mark Tattoli reported the acquisition of 250 common shares and disposition of 99 shares related to restricted stock vesting.

Core Laboratories Inc.'s CAO & Treasurer, Teo Sow Hang, reported routine acquisitions of common stock through restricted share vesting and corresponding dispositions for tax withholding.

Sow Hang Teo, CAO & Treasurer of Core Laboratories Inc., reports a transaction involving common stock and restricted shares on May 1, 2025.

Mark Damian Tattoli, SVP, Gen Counsel & Secretary of Core Laboratories Inc., reports transactions involving common stock and restricted shares on May 1, 2025.

Director Temeng Kwaku reports acquisition and disposal of Core Laboratories Inc. common stock and restricted shares on April 1, 2025.

Director Katherine Murray reports acquisition and disposal of Core Laboratories Inc. stock and restricted shares on April 1, 2025.

Director Harvey Robert Klingensmith reports acquisition and disposal of Core Laboratories Inc. common stock and restricted shares on April 1, 2025.

Director Martha Z. Carnes reports acquisition and disposal of Core Laboratories Inc. common stock and restricted shares on April 1, 2025.